![Foto de Irati](/img/nophoto.png)
Irati
Garmendia Iturbe
Investigadora hasta 2019
Publicaciones (10) Publicaciones de Irati Garmendia Iturbe
2022
-
Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas
International Journal of Molecular Sciences, Vol. 23, Núm. 19
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
-
YES1: A Novel Therapeutic Target and Biomarker in Cancer
Molecular Cancer Therapeutics, Vol. 21, Núm. 9, pp. 1371-1380
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2020
-
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas
Cancer Immunology, Immunotherapy, Vol. 69, Núm. 10, pp. 2089-2100
2019
-
The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042
Journal of Clinical Medicine, Vol. 8, Núm. 8
-
The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma
Cancers, Vol. 11, Núm. 11
-
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899
2018
-
The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer
Laboratory Investigation, Vol. 98, Núm. 12, pp. 1562-1574
2014
-
New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations
International Journal of Cancer, Vol. 135, Núm. 11, pp. 2516-2527